The Capital Map: Money Is Everywhere. The Two Things It's Chasing Aren't.
Big Pharma entered 2026 with record dealmaking capacity and a patent cliff it has to answer. This briefing maps where that money is going across radiopharma, ADCs, cell and gene therapy and next-generation biologics, and argues the binding constraints sit downstream of capital, in things a cheque cannot conjure quickly.
What this report answers
- Where is complex-modality capital actually going in 2026, and are the flows moving in the same direction?
- If capital is abundant, what is the real constraint on how large a modality can get?
- Why is manufacturing difficulty being priced as a moat in some modalities and as a cost drag in others?
- What broke in cell and gene therapy funding, and does the lesson generalise to the rest?
- What does the reversal of innovation flow out of China do to Western deal structuring?
- Which forces steer where the money goes next, and are they all pointing the same way?
$2.1 trillion
the dealmaking firepower Big Pharma carried into 2026, which the briefing cites from EY's 2026 Firepower Report while noting more conservative measures put it nearer $1.2 trillion.
$106 billion
of biotech M&A across 201 deals through early June 2026, the pace the briefing cites from PitchBook as evidence that capital is not what is holding the sector back.
What the analysis establishes
Three flows, not one
The briefing separates strategic M&A, venture financing and the exit window, and establishes that they are not moving together. It sets out the arithmetic underneath the deal floor, why the venture pool has changed shape rather than simply shrunk, and how narrow the reopened listing route actually is. The picture the three flows make is stated as one coherent market condition.
Why complex modalities is the right unit of analysis
Rather than treat radiopharma, ADCs, cell and gene therapy and next-generation biologics as separate stories, the briefing defines the economic signature they share and small molecules do not. It builds a two-bar test - science and commercial de-risking against manufacturing complexity - and positions each modality on it, noting the positions are analytical judgement rather than a precise dataset.
Where the premiums are being paid, and what they are buying
Two modality chapters work through the deal record and the private rounds behind it. The briefing establishes what the stated purpose of those rounds reveals about what acquirers and investors think they are buying, and identifies where in each value chain the value and the constraint actually concentrate rather than where the headlines sit.
The control experiment
Cell and gene therapy is treated as the case that tests the thesis by failing it. The briefing documents the funding retreat, separates what stopped working in the science from what stopped working in the economics, and traces where capital moved rather than left. It draws a lesson it argues now shapes how every other modality gets financed.
The layer that has to build all of it
The CDMO and CRO chapter is the convergence point. It sets out the demand side, the physical lead times that govern how quickly capacity can answer it, and two supply-side events inside eighteen months that changed who controls what. It also explains why one of these layers works as a leading indicator for the financing cycle.
The variables, and a forward view to 2028
A table sets out six variables governing where capital moves next - rates, US pricing policy, tariffs and onshoring, the China corridor, demographics and payer pressure, and exit recycling - each with its state at mid-2026 and its effect on flow. Six calls follow, framed explicitly as a working thesis rather than a forecast.
How it was built
A market-intelligence synthesis rather than a dataset. It draws on public company disclosures, regulatory and legislative filings, third-party deal and industry databases, market-research houses, and ProGen Search's own research and editorial judgment. Deal, policy and market figures were verified to early July 2026, and several fast-moving items were unresolved at that cut-off and are flagged for re-checking. Where sources diverge materially by scope and method the briefing gives ranges and asks the reader to treat the direction of travel, not any single number, as the finding. Exhibit positions and the closing calls are stated as judgement, not measurement.
Written for institutional investors, private equity and venture partners, corporate development teams, and operators and boards in radiopharma, ADC, cell and gene therapy, CDMO and CRO businesses planning a build-out, a scale-up or a leadership hire.
Contents
- The Central Finding
- The Shape of the Money in 2026
- Why "Complex Modalities" Is the Right Unit
- Radiopharma: The Supply Chain Is the Asset
- Antibody-Drug Conjugates
- Cell and Gene Therapy: The Control Experiment
- Next-Generation Biologics
- The Layer That Has to Build All of It
- The Variables That Govern the Money
- The Forward View, 2026 to 2028
- What It Means for Operators
Organisations covered
AbbVie, AdvanCell, Akeso, ARTBIO, Astellas, AstraZeneca, BioNTech, Bristol Myers Squibb, Catalent, Daiichi Sankyo, Eli Lilly, Fujifilm, Fusion Pharmaceuticals, ImmunoGen, Lonza, Merck, Novartis, Novo Holdings, PanTera, Pfizer, RayzeBio, Samsung Biologics, Seagen, Thermo Fisher, WuXi AppTec
The full 24-page briefing is free. Tell us where to send it and it downloads immediately.